Bladder Cancer in the Genomic Era

Area of Science:

• Uro-oncology
• Genomic Medicine
• Cancer Biology

Background:

• Bladder cancer classification traditionally relies on morphology and immunohistochemistry.
• Recent genomic studies highlight DNA and RNA alterations driving bladder cancer's heterogeneity.
• These alterations underpin diverse clinicopathologic features and suggest a novel molecular classification.

Purpose of the Study:

• To review recent advancements in genomic characterization of bladder cancer.
• To explore molecular mechanisms, including oncogenic pathways and subtyping.
• To understand the development of histologic variants in bladder cancer.

Main Methods:

• Literature review of peer-reviewed publications.
• Analysis of PubMed search results.
• Inclusion of authors' original research.

Main Results:

• Bladder cancer likely originates from distinct uroprogenitor cells via papillary/luminal and nonpapillary/basal pathways.
• Intrinsic molecular subtypes (luminal and basal) show unique expression profiles and clinical behaviors.
• These subtypes exhibit differential responses to standard chemotherapy.

Conclusions:

• Genomic characterization provides crucial insights into bladder cancer's complex biology.
• Molecular subtyping (luminal vs. basal) is key to understanding disease behavior.
• This molecular understanding may pave the way for more effective bladder cancer therapies.